Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 11Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 15Neoplasm Metastasis 5Colonic Neoplasms 2Sarcoma 1Rectal Neoplasms 1Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Capecitabine 35Oxaliplatin 32Fluorouracil 29Leucovorin 26Irinotecan 22Bevacizumab 19Cetuximab 17Radiotherapy 16Radiation 11Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Celecoxib 5Neoadjuvant Therapy 4Immunohistochemistry 4Biopsy 4Amplified Fragment Length Polymorphism Analysis 4cediranib 3Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Folfox protocol 3Drug Therapy 3Cisplatin 3sargramostim 2regorafenib 2pembrolizumab 2fludarabine phosphate 2aldesleukin 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rectal Neoplasms × IFL protocol × Clear all
NCT01347645 2023-06-22

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Eisai Inc.

Phase 1/2 Terminated
82 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡